IBDCNC (@charismaew) profile picture
Australia
Joined March 2013
Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)Photo by IBDCNC (@charismaew)
🎯
Half the Jews on Earth now live in one country the size of New Jersey. That is not colonialism. That is what a hunted people does when the last door that opens is their own.
1
40
The Women’s Policy Centre strongly opposes the appointment of the Islamic regime of Iran to key organ at the @UN shaping priorities on women's rights and terrorism prevention. We are calling on @AnitaAnandMP @MarkJCarney to reverse course. Canada can stop this travesty as @HillelNeuer rightly points out. nationalpost.com/opinion/hil…
12
112
4
337
11,126
The UN are clearly UNfit for women. We are dismayed (to say the very least) that they would even consider a country such as Iran as a member of any body that plays a role in shaping women's rights. Iran oppresses women and girls. They oppress the female sex. We'll take no lectures from the UN on the rights of women while they even entertain this. nationalpost.com/opinion/hil…
The Women’s Policy Centre strongly opposes the appointment of the Islamic regime of Iran to key organ at the @UN shaping priorities on women's rights and terrorism prevention. We are calling on @AnitaAnandMP @MarkJCarney to reverse course. Canada can stop this travesty as @HillelNeuer rightly points out. nationalpost.com/opinion/hil…
39
633
16
1,894
62,278
Two key studies in #IBD exploring elective appendectomy in the management of #UlcerativeColitis: • ACCURE (2025) • COSTA (2026) Key differences summarized below 👇
20
52
2,422
Why do some UC patients fail vedolizumab (VDZ)? A landmark study in Nature Medicine by Schreiber et al. unpacks the biological mechanism of VDZ resistance: revealing an alternative vascular bypass that might be targetable with common medications
7
49
11
117
20,932
Hyperbaric oxygen therapy for IBD? Yes says @PDulaiMD @ucsfibd If you can get it and if appropriate!
1
12
25
1,847
When is it safe to de-escalate upadacitinib from 45 mg in UC? In our newly published study, clinical and biochemical remission—not duration of induction—predicted successful dose de-escalation. Treat the patient, not the calendar. 🎯 Read more: doi.org/10.1093/crocol/otag1…
1
11
2
43
4,622
✂️ Cut, don't stretch? First RCT of stricturotomy vs balloon dilation in Crohn's Disease 📍 BEST-CD: 106 adults with short (<3 cm) symptomatic CD strictures, randomised 1:1 to endoscopic balloon dilation (EBD) or endoscopic stricturotomy (ES) 🎯 Clinical recurrence at 1 year: 30.1% with ES vs 54.7% with EBD (p=0.01) 🔁 Reintervention: 24.5% vs 49.1% · Emergency visits: 18.9% vs 50.9% · Hospitalisation: 15.1% vs 34% 🔪 Surgery 1.9% vs 11.3% (NS) · Adverse events similar (13.2% vs 22.6%) ⚠️ Expert-centre data, 1-year follow-up: needs multicentre validation 👇 The data in one image 🔗 doi.org/10.1016/j.cgh.2026.1… #MedTwitter #GITwitter #MedEd #IBD #CrohnsDisease #Endoscopy
1
12
20
1,043
Here’s the video for anyone that wants to see it.
519
3,045
201
14,463
616,657
Calprotectin could be useful in identifying at-risk individuals before #Crohnsdisease develops Dan Turner and colleagues propose a framework for identifying high-risk participants for prevention trials based on the PIONIR study 👇👇👇
📝 #GUTBlog | Could screening help pave the way for Crohn’s disease prevention? Turner et al explore how faecal calprotectin can help define preclinical stages of Crohn’s disease in asymptomatic first-degree relatives, proposing a screening framework to support future prevention trials. 📄 "Preclinical stages of Crohn’s disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials" 📝 Read the #GUTBlog: bit.ly/3UkCNxM 🔗 Read the paper in Gut: bit.ly/4zLZWYY #CrohnsDisease #IBD #FaecalCalprotectin #PreventionResearch
9
14
749
The killing of young Iranians goes on. Dont look away
The Islamic Republic continues its execution spree of young January protesters who were not given due process, and were tortured into “confessing.”
15
530
6
2,034
35,094
Evolution of treatment targets in #IBD: 👉Stride 1 (2015) 👉Stride 2 (2021) 👉Stride 3 (2026) Key differences, all in one table 👇
2
33
84
4,895
Pearls of management and approach to the refractory IBD. Dr. Rubin @IBDMD #IBDSUMMIT
12
27
2,419
Gilead has just paid $1.275bn for an oral IL-23 receptor peptide to pair with its own oral α4β7. J&J is betting its oral IL-23 receptor peptide wins on its own. Who's right? My view: the new IBD tablets will be licensed alone. But outside the US, most will only be worth paying for in combination. This is where each one acts in the gut wall. The best pairs hit different mechanisms, not the same one twice. Combination therapy in IBD, Part 2: is an IBD polypill realistic? Tomorrow on Atomic IBD.
4
17
1
71
5,774
Eight years ago I had the idea of combining ustekinumab and vedolizumab after anti-TNF failure in Crohn's disease. Each drug alone only went so far. Would the two together do better? At UEG Week, Remo Panaccione presented the first data on ABBV-466, AbbVie's combination of risankizumab with trosunilimab, a new anti-α4β7 antibody. Trosunilimab isn't vedolizumab, and it isn't a biosimilar of it. It's a new human antibody that AbbVie first developed for HIV research. In their lab work it binds α4β7 about 13 times more tightly than a comparator built from published sequences. So α4β7 is back as a target in Crohn's disease, this time as a partner for IL-23 blockade. AbbVie's tissue data, not yet published, show why that might work. In CD tissue, the IL-23 receptor and α4β7 sit on mostly different cells. Risankizumab alone leaves most of the gut-homing cells untouched. The trial was part of the TARGET-CD platform study. It took 300 adults with moderate to severe CD, and three quarters had already failed an advanced therapy. They were randomised to risankizumab, trosunilimab or both (ABBV-466). Endoscopic remission at week 12 was 30% on the combination, against 21% and 18% on each drug alone. By week 24 it was 41% against 22% and 20%. The combination almost doubled the rate and was still climbing, while each drug alone had levelled off. By week 24, more than half on the combination had an endoscopic response. The pattern held in people who had already failed an advanced therapy: 40% against 21% and 13% at week 24. Early transcriptomics from small biopsy subsets look interesting too. Epithelial repair and barrier genes rose by week 12, and tissue repair, nerve growth and vitamin transport genes by week 24, mainly on the combination. Safety looked similar across the three arms. It's phase 2a and open-label. The only p-value is nominal, at week 24. Clinical remission wasn't presented, and the doses haven't been disclosed. But AbbVie is already running a blinded phase 2 platform study in around 2,000 people with CD and UC, which includes ABBV-466 at two doses. The harder test is under way. I should have run that study eight years ago. Of course, no one would have funded it back then!
1
25
77
6,407